Innate sensors of influenza virus: clues to developing better intranasal vaccines

References

• Smidt MH, Stroink H, Bruinenberg JF, Peeters M. Encephalopathy associated with influenza A. Eur. J. Paediatr. Neurol.8(5), 257–260 (2004).
   PubMedGoogle Scholar
• Wada N. Influenza-associated encephalopathy. Nippon rinsho62(Suppl. 5) 456–461 (2004).
   PubMedGoogle Scholar
• Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Eng. J. Med.352(4), 333–340 (2005).
   PubMed Web of Science ®Google Scholar
• Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis.11(10), 1515–1521 (2005).
   PubMed Web of Science ®Google Scholar
• Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature437(7062), 1108 (2005).
   PubMed Web of Science ®Google Scholar
• Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nature Med.8(9), 950–954 (2002).
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature413(6857), 732–738 (2001).
   PubMed Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science303(5663), 1529–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA101(15), 5598–5603 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J. Immunol.173(11), 6882–6889 (2004).
   PubMedGoogle Scholar
• Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol.80(10), 5059–5064 (2006).
   PubMed Web of Science ®Google Scholar
• Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5´-phosphates. Science314(5801), 997–1001 (2006).
   PubMed Web of Science ®Google Scholar
• Bracci L, Canini I, Puzelli S et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine23(23), 2994–3004 (2005).
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science303(5663), 1526–1529 (2004).
   PubMed Web of Science ®Google Scholar
• Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med.198(3), 513–520 (2003).
   PubMed Web of Science ®Google Scholar
• Asselin-Paturel C, Boonstra A, Dalod M et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol.2(12), 1144–1150 (2001).
   PubMed Web of Science ®Google Scholar
• Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science315(5817), 1398–1401 (2007).
   PubMed Web of Science ®Google Scholar
• Crozat K, Beutler B. TLR7: a new sensor of viral infection. Proc. Natl Acad. Sci. USA101(18), 6835–6836 (2004).
   PubMed Web of Science ®Google Scholar
• Reise Sousa C. Immunology. Eating in to avoid infection. Science315(5817), 1376–1377 (2007).
   PubMedGoogle Scholar
• Iwasaki A. Role of autophagy in innate viral recognition. Autophagy3(4), 354–356 (2007).
   PubMed Web of Science ®Google Scholar
• Lee HK, Iwasaki A. Autophagy and antiviral immunity. Curr. Opin. Immunol.20(1), 23–29 (2008).
   PubMedGoogle Scholar
• Kumagai Y, Takeuchi O, Kato H et al. Alveolar macrophages are the primary interferon-α producer in pulmonary infection with RNA viruses. Immunity27(2), 240–252 (2007).
   PubMedGoogle Scholar
• Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J. Infect. Chemother.14(2), 86–92 (2008).
   PubMedGoogle Scholar
• Guo Z, Chen LM, Zeng H et al. NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am. J. Resp. Cell Mol. Biol.36(3), 263–269 (2007).
   PubMed Web of Science ®Google Scholar
• Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M Jr, Garcia-Sastre A. Inhibition of retinoic acid-inducible gene I-mediated induction of β interferon by the NS1 protein of influenza A virus. J. Virol.81(2), 514–524 (2007).
   PubMed Web of Science ®Google Scholar
• Opitz B, Rejaibi A, Dauber B et al. IFNβ induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cell. Microbiol.9(4), 930–938 (2007).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol.5(7), 730–737 (2004).
   PubMed Web of Science ®Google Scholar
• Kato H, Sato S, Yoneyama M et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity23(1), 19–28 (2005).
   PubMed Web of Science ®Google Scholar
• Andrejeva J, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, MDA-5, and inhibit its activation of the IFN-β promoter. Proc. Natl Acad. Sci. USA101(49), 17264–17269 (2004).
   PubMed Web of Science ®Google Scholar
• Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. MDA-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl Acad. Sci. USA99(2), 637–642 (2002).
   PubMed Web of Science ®Google Scholar
• Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I- and MDA5-mediated type I interferon induction. Nat. Immunol.6(10), 981–988 (2005).
   PubMed Web of Science ®Google Scholar
• Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell122(5), 669–682 (2005).
   PubMed Web of Science ®Google Scholar
• Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature437(7062), 1167–1172 (2005).
   PubMed Web of Science ®Google Scholar
• Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-β signaling. Mol. Cell19(6), 727–740 (2005).
   PubMed Web of Science ®Google Scholar
• Moore CB, Bergstralh DT, Duncan JA et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature451(7178), 573–577 (2008).
   PubMedGoogle Scholar
• Tattoli I, Carneiro LA, Jehanno M et al. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-κB and JNK pathways by inducing reactive oxygen species production. EMBO Reports9(3), 293–300 (2008).
   PubMedGoogle Scholar
• Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature441(7089), 101–105 (2006).
   PubMed Web of Science ®Google Scholar
• Gitlin L, Barchet W, Gilfillan S et al. Essential role of MDA-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA103(22), 8459–8464 (2006).
   PubMed Web of Science ®Google Scholar
• Hornung V, Ellegast J, Kim S et al. 5´-triphosphate RNA is the ligand for RIG-I. Science314(5801), 994–997 (2006).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Onomoto K, Fujita T. Cytoplasmic recognition of RNA. Adv. Drug. Deliv. Rev.60(7), 841–846 (2008).
   PubMedGoogle Scholar
• Kato H, Takeuchi O, Mikamo-Satoh E et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med.205(7), 1601–1610 (2008).
   PubMed Web of Science ®Google Scholar
• Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature454(7203), 523–527 (2008).
   PubMed Web of Science ®Google Scholar
• Saito T, Gale M Jr. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med.205(7), 1523–1527 (2008).
   PubMed Web of Science ®Google Scholar
• Koyama S, Ishii KJ, Kumar H et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol.179(7), 4711–4720 (2007).
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev.1(2), 135–145 (2001).
   Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol.5(10), 987–995 (2004).
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature438(7066), 364–368 (2005).
   PubMed Web of Science ®Google Scholar
• McGill J, Van Rooijen N, Legge KL. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J. Exp. Med.205(7), 1635–1646 (2008).
   PubMed Web of Science ®Google Scholar
• GeurtsvanKessel CH, Willart MA, van Rijt LS et al. Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J. Exp. Med.205(7), 1621–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Heer AK, Shamshiev A, Donda A et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol.178(4), 2182–2191 (2007).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol.79(5), 2910–2919 (2005).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Tamura S, Kawaguchi A et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis.196(9), 1313–1320 (2007).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Kawaguchi A, Tamura S et al. Intranasal immunization with H5N1 vaccine plus poly I:poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect.9(11), 1333–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat. Rev.7(1), 31–40 (2007).
   Google Scholar
• Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell126(4), 659–662 (2006).
   PubMed Web of Science ®Google Scholar
• Werts C, Girardin SE, Philpott DJ. TIR, CARD and PYRIN: three domains for an antimicrobial triad. Cell Death Differ.13(5), 798–815 (2006).
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature442(7098), 39–44 (2006).
   PubMed Web of Science ®Google Scholar
• Freche B, Reig N, van der Goot FG. The role of the inflammasome in cellular responses to toxins and bacterial effectors. Semin. Immunopathol.29(3), 249–260 (2007).
   PubMedGoogle Scholar
• Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell117(5), 561–574 (2004).
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Hashimoto M, Horie Y et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol.4(7), 702–707 (2003).
   PubMed Web of Science ®Google Scholar
• Keller M, Ruegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell132(5), 818–831 (2008).
   PubMed Web of Science ®Google Scholar
• Kuida K, Lippke JA, Ku G et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 β converting enzyme. Science267(5206), 2000–2003 (1995).
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol,20(5 Suppl. 27), S1–S13 (2002).
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity23(5), 479–490 (2005).
   PubMed Web of Science ®Google Scholar
• Ting JP, Lovering RC, Alnemri ES et al. The NLR gene family: a standard nomenclature. Immunity28(3), 285–287 (2008).
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature425(6957), 516–521 (2003).
   PubMed Web of Science ®Google Scholar
• Kanneganti TD, Ozoren N, Body-Malapel M et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature440(7081), 233–236 (2006).
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature440(7081), 228–232 (2006).
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature440(7081), 237–241 (2006).
   PubMed Web of Science ®Google Scholar
• Sutterwala FS, Ogura Y, Szczepanik M et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity24(3), 317–327 (2006).
   PubMed Web of Science ®Google Scholar
• Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science320(5876), 674–677 (2008).
   PubMed Web of Science ®Google Scholar
• Walev I, Klein J, Husmann M et al. Potassium regulates IL-1 β processing via calcium-independent phospholipase A2. J. Immunol.164(10), 5120–5124 (2000).
   PubMedGoogle Scholar
• Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 β secretion: implications for inflammatory processes. Proc. Natl Acad. Sci. USA101(26), 9745–9750 (2004).
   PubMed Web of Science ®Google Scholar
• Wewers MD. IL-1β: an endosomal exit. Proc. Natl Acad. Sci. USA101(28), 10241–10242 (2004).
   PubMedGoogle Scholar
• Fernandes-Alnemri T, Wu J, Yu JW et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ.14(9), 1590–1604 (2007).
   PubMed Web of Science ®Google Scholar
• Saleh M, Green DR. Caspase-1 inflammasomes: choosing between death and taxis. Cell Death Differ.14(9), 1559–1560 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrari D, Pizzirani C, Adinolfi E et al. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol.176(7), 3877–3883 (2006).
   PubMed Web of Science ®Google Scholar
• Kanneganti TD, Body-Malapel M, Amer A et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem.281(48), 36560–36568 (2006).
   PubMed Web of Science ®Google Scholar
• Johnston JB, Barrett JW, Nazarian SH et al. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity23(6), 587–598 (2005).
   PubMed Web of Science ®Google Scholar
• Muruve DA, Petrilli V, Zaiss AK et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature452(7183), 103–107 (2008).
   PubMed Web of Science ®Google Scholar
• Vacheron F, Rudent A, Perin S, Labarre C, Quero AM, Guenounou M. Production of interleukin 1 and tumour necrosis factor activities in bronchoalveolar washings following infection of mice by influenza virus. J. Gen. Virol.71(Pt. 2), 477–479 (1990).
   PubMed Web of Science ®Google Scholar
• Hennet T, Ziltener HJ, Frei K, Peterhans E. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J. Immunol.149(3), 932–939 (1992).
   PubMed Web of Science ®Google Scholar
• Pirhonen J, Sareneva T, Kurimoto M, Julkunen I, Matikainen S. Virus infection activates IL-1 β and IL-18 production in human macrophages by a caspase-1-dependent pathway. J. Immunol.162(12), 7322–7329 (1999).
   PubMedGoogle Scholar
• Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol.79(10), 6441–6448 (2005).
   PubMed Web of Science ®Google Scholar
• Stasakova J, Ferko B, Kittel C et al. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1β and 18. J. Gen. Virol.86(Pt. 1), 185–195 (2005).
   PubMed Web of Science ®Google Scholar
• Akaike T, Ando M, Oda T et al. Dependence on O2- generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J. Clin. Invest.85(3), 739–745 (1990).
   PubMed Web of Science ®Google Scholar
• Behrens MD, Wagner WM, Krco CJ et al. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood111(3), 1472–1479 (2008).
   PubMedGoogle Scholar
• Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis.58(4), 195–207 (2005).
   PubMed Web of Science ®Google Scholar
• Asahi Y, Yoshikawa T, Watanabe I et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol.168(6), 2930–2938 (2002).
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Ichinohe T, Tamura S, Kurata T. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert Rev. Vaccines6(2), 193–201 (2007).
   PubMed Web of Science ®Google Scholar
• Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol.69(2), 1339–1343 (1995).
   PubMed Web of Science ®Google Scholar
• Ito R, Ozaki YA, Yoshikawa T et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine21(19–20), 2362–2371 (2003).
   PubMed Web of Science ®Google Scholar
• Tamura SI, Kurata T. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn. J. Infect. Dis.53(3), 98–106 (2000).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol.165(9), 4778–4782 (2000).
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Nagata N, Strong P et al. Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus. J. Med. Virol.79(6), 811–819 (2007).
   PubMedGoogle Scholar
• Ichinohe T, Watanabe I, Tao E et al. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. J. Med. Virol.78(7), 954–963 (2006).
   PubMed Web of Science ®Google Scholar
• Kamijuku H, Nagata Y, Jiang X et al. Mechanism of NKT cell activation by intranasal coadministration of a-galactosylceramide, which can induce cross-protection against influenza viruses. Muc. Immunol.1(3), 208–218 (2008).
   PubMed Web of Science ®Google Scholar
• Asahi-Ozaki Y, Itamura S, Ichinohe T et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect.8(12–13), 2706–2714 (2006).
   PubMed Web of Science ®Google Scholar
• Palese P. Making better influenza virus vaccines? Emerg. Infect. Dis.12(1), 61–65 (2006).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther.82(6), 740–744 (2007).
   PubMed Web of Science ®Google Scholar
• Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug. Deliv. Rev.51(1–3), 149–159 (2001).
   PubMed Web of Science ®Google Scholar
• Hartshorn KL, Crouch EC, White MR et al. Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J. Clin. Invest.94(1), 311–319 (1994).
   PubMed Web of Science ®Google Scholar
• Benne CA, Kraaijeveld CA, van Strijp JA et al. Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J. Infect. Dis.171(2), 335–341 (1995).
   PubMedGoogle Scholar
• Hartshorn KL, Sastry K, Brown D et al. Conglutinin acts as an opsonin for influenza A viruses. J. Immunol.151(11), 6265–6273 (1993).
   PubMedGoogle Scholar
• Hartshorn KL, Sastry K, White MR et al. Human mannose-binding protein functions as an opsonin for influenza A viruses. J. Clin. Invest.91(4), 1414–1420 (1993).
   PubMedGoogle Scholar
• LeVine AM, Whitsett JA. Pulmonary collectins and innate host defense of the lung. Microbes Infect.3(2), 161–166 (2001).
   PubMed Web of Science ®Google Scholar
• Jia W, Li H, He YW. Pattern recognition molecule mindin promotes intranasal clearance of influenza viruses. J. Immunol.180(9), 6255–6261 (2008).
   PubMedGoogle Scholar
• Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J. Virol.60(3), 1068–1074 (1986).
   PubMed Web of Science ®Google Scholar
• Leikina E, Delanoe-Ayari H, Melikov K et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol.6(10), 995–1001 (2005).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sato S, Hemmi H et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science301(5633), 640–643 (2003).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity14(4), 461–470 (2001).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol.4(10), 1009–1015 (2003).
   PubMed Web of Science ®Google Scholar
• Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic–polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res.23(6), 1217–1226 (2006).
   PubMed Web of Science ®Google Scholar
• Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J. Immunol.180(2), 683–687 (2008).
   PubMed Web of Science ®Google Scholar
• Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A Phase I–II trial of multiple-dose polyriboinosic–polyribocytidylic acid in patieonts with leukemia or solid tumors. J. Natl Cancer Inst.57(3), 599–602 (1976).
   PubMedGoogle Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P et al. Changes in the 2–5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)–poly(C12U) in chronic fatigue syndrome. In Vivo8(4), 599–604 (1994).
   PubMedGoogle Scholar
• Ashkenazi S, Vertruyen A, Aristegui J et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr. Infect. Dis. J.25(10), 870–879 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Fleming DM, Aristegui JF et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics118(6), 2298–2312 (2006).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.356(7), 685–696 (2007).
   PubMed Web of Science ®Google Scholar
• Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J. Infect. Dis.144(5), 433–441 (1981).
   PubMedGoogle Scholar
• Hall CB, Douglas RG Jr, Geiman JM, Meagher MP. Viral shedding patterns of children with influenza B infection. J. Infect. Dis.140(4), 610–613 (1979).
   PubMedGoogle Scholar
• Long CE, Hall CB, Cunningham CK et al. Influenza surveillance in community-dwelling elderly compared with children. Arch. Fam. Med.6(5), 459–465 (1997).
   PubMedGoogle Scholar
• Wright PF, Ross KB, Thompson J, Karzon DT. Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N. Engl. J. Med.296(15), 829–834 (1977).
   PubMed Web of Science ®Google Scholar
• Talon J, Salvatore M, O’Neill RE et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl Acad. Sci. USA97(8), 4309–4314 (2000).
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH et al. TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol.178(8), 5200–5208 (2007).
   PubMed Web of Science ®Google Scholar
• Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine25(18), 3554–3560 (2007).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature453, 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar